|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ITLN1 |
Gene summary for ITLN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ITLN1 | Gene ID | 55600 |
| Gene name | intelectin 1 | |
| Gene Alias | HL-1 | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q8WWA0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55600 | ITLN1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.05e-06 | 6.24e-01 | -0.1808 |
| 55600 | ITLN1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.00e-03 | 8.21e-01 | -0.0811 |
| 55600 | ITLN1 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.40e-20 | 1.61e+00 | -0.1088 |
| 55600 | ITLN1 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.50e-11 | 2.93e+00 | -0.2602 |
| 55600 | ITLN1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.88e-11 | 2.67e+00 | -0.2196 |
| 55600 | ITLN1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.38e-26 | 2.01e+00 | -0.1207 |
| 55600 | ITLN1 | HTA11_83_2000001011 | Human | Colorectum | SER | 7.35e-06 | 3.11e-01 | -0.1526 |
| 55600 | ITLN1 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.71e-40 | 2.20e+00 | -0.1464 |
| 55600 | ITLN1 | HTA11_866_2000001011 | Human | Colorectum | AD | 9.45e-17 | 1.59e+00 | -0.1001 |
| 55600 | ITLN1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.37e-03 | 5.38e-01 | -0.059 |
| 55600 | ITLN1 | HTA11_546_2000001011 | Human | Colorectum | AD | 8.36e-09 | 1.90e+00 | -0.0842 |
| 55600 | ITLN1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.00e-02 | 9.59e-02 | 0.096 |
| 55600 | ITLN1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 3.42e-04 | 1.03e+00 | 0.3487 |
| 55600 | ITLN1 | A015-C-005 | Human | Colorectum | FAP | 9.35e-08 | 3.65e-01 | -0.0336 |
| 55600 | ITLN1 | Pat01-B | Human | Stomach | GC | 9.91e-29 | -1.01e+00 | 0.5754 |
| 55600 | ITLN1 | Pat02-B | Human | Stomach | GC | 1.22e-36 | -1.09e+00 | 0.0368 |
| 55600 | ITLN1 | Pat03-B | Human | Stomach | GC | 3.49e-30 | -1.10e+00 | 0.3693 |
| 55600 | ITLN1 | Pat04-B | Human | Stomach | GC | 3.06e-13 | -1.02e+00 | -0.1483 |
| 55600 | ITLN1 | Pat05-B | Human | Stomach | GC | 2.10e-15 | -1.12e+00 | -0.0353 |
| 55600 | ITLN1 | Pat06-B | Human | Stomach | GC | 3.21e-40 | -1.20e+00 | -0.1961 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00347641 | Colorectum | FAP | positive regulation of transmembrane transport | 53/2622 | 219/18723 | 3.54e-05 | 7.75e-04 | 53 |
| GO:0046323 | Colorectum | FAP | glucose import | 20/2622 | 74/18723 | 2.36e-03 | 1.88e-02 | 20 |
| GO:0046324 | Colorectum | FAP | regulation of glucose import | 16/2622 | 59/18723 | 5.95e-03 | 3.75e-02 | 16 |
| GO:0010827 | Colorectum | FAP | regulation of glucose transmembrane transport | 19/2622 | 77/18723 | 8.67e-03 | 4.98e-02 | 19 |
| GO:0010828 | Colorectum | FAP | positive regulation of glucose transmembrane transport | 13/2622 | 46/18723 | 8.71e-03 | 4.98e-02 | 13 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ITLN1 | SNV | Missense_Mutation | c.709C>G | p.Gln237Glu | p.Q237E | Q8WWA0 | protein_coding | deleterious(0.02) | benign(0.059) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ITLN1 | SNV | Missense_Mutation | c.643G>A | p.Asp215Asn | p.D215N | Q8WWA0 | protein_coding | tolerated(0.26) | benign(0.019) | TCGA-BH-A1ET-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ITLN1 | SNV | Missense_Mutation | rs748741191 | c.232G>A | p.Gly78Ser | p.G78S | Q8WWA0 | protein_coding | deleterious(0.04) | possibly_damaging(0.666) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ITLN1 | SNV | Missense_Mutation | rs372272812 | c.139N>A | p.Glu47Lys | p.E47K | Q8WWA0 | protein_coding | tolerated(0.91) | benign(0) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| ITLN1 | SNV | Missense_Mutation | rs375323097 | c.292N>A | p.Asp98Asn | p.D98N | Q8WWA0 | protein_coding | deleterious(0.03) | possibly_damaging(0.534) | TCGA-PN-A8MA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| ITLN1 | SNV | Missense_Mutation | novel | c.221C>T | p.Ser74Phe | p.S74F | Q8WWA0 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ITLN1 | SNV | Missense_Mutation | rs147176765 | c.253G>A | p.Val85Met | p.V85M | Q8WWA0 | protein_coding | deleterious(0.04) | probably_damaging(0.971) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ITLN1 | SNV | Missense_Mutation | c.352N>A | p.Ala118Thr | p.A118T | Q8WWA0 | protein_coding | tolerated(0.06) | possibly_damaging(0.856) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
| ITLN1 | SNV | Missense_Mutation | novel | c.869N>A | p.Gly290Glu | p.G290E | Q8WWA0 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ITLN1 | SNV | Missense_Mutation | novel | c.844N>T | p.Asp282Tyr | p.D282Y | Q8WWA0 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |